Tumor Lysis Syndrome

Description

Tumor lysis syndrome is a life-threatening metabolic emergency frequently associated with certain types of neoplasms. Concentrations of intracellular electrolytes, those that are within the cell, differ from extracellular electrolytes, or those that are outside the cell and in the bloodstream. In tumor lysis syndrome, tumor cells lyse, or break apart, releasing their contents into the blood stream. The result is a dangerous alteration in the normal balance of serum electrolytes—potassium, phosphate and uric acid levels are elevated, while calcium levels are decreased. The changes occur so quickly and can be so dramatic, that immediate death can result.

Causes

Many factors contribute to the development of tumor lysis syndrome. Most of the research performed to date revolves around high-grade non-Hodgkin's lymphoma cases, 40% of which demonstrate laboratory evidence of tumor lysis syndrome. (An estimated 6% demonstrate clinical evidence of the syndrome.) Tumors that carry the highest risk of the development of tumor lysis syndrome are those that are large and bulky, usually greater than eight to ten cm (3-4 in), and comprised of rapidly dividing cells. In addition, tumors that respond well to treatment are associated with tumor lysis syndrome because treatment results in rupture of a large number of cells.

Most often, the syndrome is associated with hemato-logic tumors, such as non-Hodgkin's lymphoma, particularly Burkitt's lymphoma, and acute leukemia. Though less likely because of lower rates of cell division, tumor lysis syndrome can also occur in solid tumors such as breast cancer. The Washington Manual of Medical Therapeutics associates the following cancer types with tumor lysis syndrome:

Usually, tumor lysis syndrome develops after the administration of combination chemotherapy regimens, but it may also occur spontaneously or as a result of radiation or corticosteroid therapy. Lactic acid dehydrogenase (LDH) is an enzyme found in cells of body tissues. An increase in the LDH level is considered a marker of bulky disease that correlates with the risk of tumor lysis syndrome.

Patients with underlying renal (kidney) dysfunction and/or decreased urine output are at a higher risk of developing tumor lysis syndrome. Without optimal kidney functioning, waste products that build up cannot be excreted in the urine at high enough rate. Patients with cancer may be predisposed to conditions that increase the risk of renal failure due to increased uric acid buildup. For example, a patient undergoing chemotherapy may experience nausea and vomiting, and may, as a result, be dehydrated, increasing the risk. The same patient may have decreased white blood cell counts, making him or her more susceptible to infections. Many antibiotics adversely affect the kidneys, also increasing the risk.


Advertisement
Advertisement